XBIT
XBiotech Inc.
Price Chart
Latest Quote
$2.48
Current Price| Previous Close | $2.51 |
| Open | $2.53 |
| Day High | $2.66 |
| Day Low | $2.42 |
| Volume | 42,392 |
Stock Information
| Shares Outstanding | 30.49M |
| Cash Equivalents | $147.37M |
| Net Income | $-29.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $75.61M |
| EPS (TTM) | $-0.95 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.06 |
| Debt to Earnings | -0.27 |
| Current Ratio | 11.56 |
| Quick Ratio | 11.49 |
| Avg Revenue Growth | -25.00% |
| Return on Equity | -21.14% |
| Avg FCF Growth | -37.24% |
| FCF Yield | -42.68% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $2.48 | 62,500 |
| 2026-01-30 | $2.51 | 9,100 |
| 2026-01-29 | $2.54 | 30,800 |
| 2026-01-28 | $2.64 | 17,000 |
| 2026-01-27 | $2.71 | 52,600 |
| 2026-01-26 | $2.69 | 45,400 |
| 2026-01-23 | $2.68 | 17,700 |
| 2026-01-22 | $2.66 | 60,700 |
| 2026-01-21 | $2.55 | 35,900 |
| 2026-01-20 | $2.53 | 72,700 |
| 2026-01-16 | $2.57 | 9,300 |
| 2026-01-15 | $2.53 | 60,900 |
| 2026-01-14 | $2.61 | 48,800 |
| 2026-01-13 | $2.56 | 19,200 |
| 2026-01-12 | $2.53 | 23,500 |
| 2026-01-09 | $2.56 | 37,200 |
| 2026-01-08 | $2.65 | 165,000 |
| 2026-01-07 | $2.51 | 75,600 |
| 2026-01-06 | $2.53 | 47,300 |
| 2026-01-05 | $2.44 | 39,300 |
About XBiotech Inc.
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes true human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases. The company is also developing interleukin-1 alpha therapies to various medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
đ° Latest News
3 Promising Penny Stocks With Market Caps Over $30M
Simply Wall St. âĸ 2025-12-19T18:05:17Z
November 2025's Promising Penny Stocks To Watch
Simply Wall St. âĸ 2025-11-12T18:05:26Z
XBiotech: Q3 Earnings Snapshot
Associated Press Finance âĸ 2025-11-12T16:55:33ZXBiotech Inc.'s (NASDAQ:XBIT) top owners are retail investors with 52% stake, while 36% is held by insiders
Simply Wall St. âĸ 2025-08-28T10:04:25Z
XBiotech: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-13T18:55:30Z3 Promising Penny Stocks With Market Caps Above $90M
Simply Wall St. âĸ 2025-07-02T18:05:41Z
Here's Why We're Not Too Worried About XBiotech's (NASDAQ:XBIT) Cash Burn Situation
Simply Wall St. âĸ 2025-05-16T11:25:04Z
XBiotech: Q1 Earnings Snapshot
Associated Press Finance âĸ 2025-05-14T19:58:55ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $4,010,000 | $18,394,000 |
| Operating Revenue | $0 | $0 | $4,010,000 | $18,394,000 |
| Reconciled Cost Of Revenue | - | $0 | $651,000 | $5,820,000 |
| Cost Of Revenue | - | $0 | $651,000 | $5,820,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $807,000 | $0 | - | - |
| Total Expenses | $42,471,000 | $37,510,000 | $38,500,000 | $43,476,000 |
| Other Income Expense | $-5,097,000 | $2,776,000 | $-2,921,000 | $-843,000 |
| Other Non Operating Income Expenses | $432,000 | $883,000 | $-121,000 | $-132,000 |
| Net Non Operating Interest Income Expense | $9,005,000 | $10,421,000 | $3,823,000 | $467,000 |
| Interest Expense Non Operating | $807,000 | $0 | - | - |
| Operating Expense | $42,471,000 | $37,510,000 | $37,849,000 | $37,656,000 |
| General And Administrative Expense | $4,714,000 | $4,662,000 | $6,305,000 | $9,388,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Net Interest Income | $9,005,000 | $10,421,000 | $3,823,000 | $467,000 |
| Interest Income | $9,812,000 | $10,421,000 | $3,823,000 | $467,000 |
| Normalized Income | $-33,007,529 | $-26,052,470 | $-30,156,000 | $-16,927,676 |
| Net Income From Continuing And Discontinued Operation | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Total Operating Income As Reported | $-42,471,000 | $-37,510,000 | $-34,490,000 | $-25,082,000 |
| Net Income Common Stockholders | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Net Income | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Net Income Including Noncontrolling Interests | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Net Income Continuous Operations | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Pretax Income | $-38,563,000 | $-24,313,000 | $-33,588,000 | $-25,458,000 |
| Interest Income Non Operating | $9,812,000 | $10,421,000 | $3,823,000 | $467,000 |
| Operating Income | $-42,471,000 | $-37,510,000 | $-34,490,000 | $-25,082,000 |
| Gross Profit | - | $0 | $3,359,000 | $12,574,000 |
| Special Income Charges | - | - | - | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-1.26 | $-0.81 | $-1.08 | $-0.58 |
| Basic EPS | $-1.26 | $-0.81 | $-1.08 | $-0.58 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-5,529 | $397,530 | $-56,000 | $-224,676 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-30,482,000 | $-24,462,000 | $-29,076,000 | $-21,723,000 |
| Total Unusual Items | $-5,529,000 | $1,893,000 | $-2,800,000 | $-711,000 |
| Total Unusual Items Excluding Goodwill | $-5,529,000 | $1,893,000 | $-2,800,000 | $-711,000 |
| Reconciled Depreciation | $1,745,000 | $1,744,000 | $2,614,000 | $2,648,000 |
| EBITDA (Bullshit earnings) | $-36,011,000 | $-22,569,000 | $-31,876,000 | $-22,434,000 |
| EBIT | $-37,756,000 | $-24,313,000 | $-34,490,000 | $-25,082,000 |
| Diluted Average Shares | $30,460,980 | $30,438,459 | $30,439,275 | $30,043,380 |
| Basic Average Shares | $30,460,980 | $30,438,459 | $30,439,275 | $30,043,380 |
| Diluted NI Availto Com Stockholders | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Tax Provision | $-32,000 | $244,000 | $-688,000 | $-8,044,000 |
| Gain On Sale Of Security | $-5,529,000 | $1,893,000 | $-2,800,000 | $-711,000 |
| Research And Development | $37,757,000 | $32,848,000 | $31,544,000 | $28,268,000 |
| Selling General And Administration | $4,714,000 | $4,662,000 | $6,305,000 | $9,388,000 |
| Other Gand A | $2,564,000 | $2,916,000 | $2,390,000 | $3,255,000 |
| Salaries And Wages | $2,150,000 | $1,746,000 | $3,915,000 | $6,133,000 |
| Gain On Sale Of Ppe | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $182,268,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Total Assets | $199,093,000 | $226,615,000 | $246,103,000 | $275,177,000 |
| Total Non Current Assets | $24,526,000 | $24,897,000 | $26,260,000 | $28,307,000 |
| Current Assets | $174,567,000 | $201,718,000 | $219,843,000 | $246,870,000 |
| Other Current Assets | $1,032,000 | $760,000 | $601,000 | $934,000 |
| Receivables | $858,000 | $935,000 | $1,764,000 | $8,953,000 |
| Taxes Receivable | $158,000 | $75,000 | $548,000 | $8,953,000 |
| Accrued Interest Receivable | $700,000 | $860,000 | $1,216,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $172,677,000 | $200,023,000 | $217,478,000 | $236,983,000 |
| Cash And Cash Equivalents | $172,677,000 | $200,023,000 | $157,306,000 | $236,983,000 |
| Non Current Deferred Assets | - | - | - | $0 |
| Non Current Deferred Taxes Assets | - | - | - | $0 |
| Current Deferred Assets | - | - | - | $0 |
| Restricted Cash | - | - | - | $0 |
| Prepaid Assets | - | - | - | $934,000 |
| Accounts Receivable | - | - | - | $0 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $10,250,000 | - | - | - |
| Current Debt And Capital Lease Obligation | $10,250,000 | - | - | - |
| Current Debt | $10,250,000 | - | - | - |
| Other Current Borrowings | $10,250,000 | - | - | - |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $16,825,000 | $7,769,000 | $5,701,000 | $5,792,000 |
| Total Non Current Liabilities Net Minority Interest | $1,720,000 | $1,669,000 | $1,635,000 | $2,339,000 |
| Tradeand Other Payables Non Current | $1,720,000 | $1,669,000 | $1,576,000 | $1,466,000 |
| Current Liabilities | $15,105,000 | $6,100,000 | $4,066,000 | $3,453,000 |
| Payables And Accrued Expenses | $4,244,000 | $5,538,000 | $3,577,000 | $2,973,000 |
| Interest Payable | $404,000 | $0 | - | - |
| Payables | $2,223,000 | $2,599,000 | $2,463,000 | $2,079,000 |
| Total Tax Payable | $0 | $83,000 | $55,000 | $10,000 |
| Income Tax Payable | $0 | $83,000 | $55,000 | $10,000 |
| Accounts Payable | $2,223,000 | $2,516,000 | $2,408,000 | $2,069,000 |
| Non Current Deferred Liabilities | - | $0 | $59,000 | $873,000 |
| Non Current Deferred Taxes Liabilities | - | $0 | $59,000 | $873,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $182,268,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Total Equity Gross Minority Interest | $182,268,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Stockholders Equity | $182,268,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Retained Earnings | $-90,837,000 | $-52,306,000 | $-27,749,000 | $5,151,000 |
| Gains Losses Not Affecting Retained Earnings | - | $0 | $826,000 | $1,971,000 |
| Other Equity Adjustments | - | - | $826,000 | $1,971,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $30,487,731 | $30,436,964 | $30,439,275 | $30,439,275 |
| Share Issued | $30,487,731 | $30,436,964 | $30,439,275 | $30,439,275 |
| Tangible Book Value | $182,268,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Invested Capital | $192,518,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Working Capital | $159,462,000 | $195,618,000 | $215,777,000 | $243,417,000 |
| Total Capitalization | $182,268,000 | $218,846,000 | $240,402,000 | $269,385,000 |
| Capital Stock | $273,105,000 | $271,152,000 | $267,325,000 | $262,263,000 |
| Common Stock | $273,105,000 | $271,152,000 | $267,325,000 | $262,263,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $611,000 | $562,000 | $489,000 | $480,000 |
| Current Accrued Expenses | $2,021,000 | $2,939,000 | $1,114,000 | $894,000 |
| Net PPE | $24,526,000 | $24,897,000 | $26,260,000 | $28,307,000 |
| Accumulated Depreciation | $-19,985,000 | $-18,239,000 | $-16,495,000 | $-15,732,000 |
| Gross PPE | $44,511,000 | $43,136,000 | $42,755,000 | $44,039,000 |
| Construction In Progress | $1,705,000 | $469,000 | $401,000 | $2,061,000 |
| Other Properties | $16,491,000 | $16,367,000 | $16,059,000 | $16,829,000 |
| Machinery Furniture Equipment | $724,000 | $709,000 | $704,000 | $958,000 |
| Buildings And Improvements | $24,173,000 | $24,173,000 | $24,173,000 | $22,773,000 |
| Land And Improvements | $1,418,000 | $1,418,000 | $1,418,000 | $1,418,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | - | $0 | $60,172,000 | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-32,267,000 | $-19,087,000 | $-15,409,000 | $65,920,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-30,963,000 | $-18,725,000 | $-14,824,000 | $69,445,000 |
| Cash Flow From Continuing Operating Activities | $-30,963,000 | $-18,725,000 | $-14,824,000 | $69,445,000 |
| Operating Gains Losses | $5,529,000 | $-1,893,000 | $2,800,000 | - |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-1,304,000 | $-362,000 | $-585,000 | $-3,525,000 |
| Investing Cash Flow | $-1,304,000 | $61,497,000 | $-63,892,000 | $-3,525,000 |
| Cash Flow From Continuing Investing Activities | $-1,304,000 | $61,497,000 | $-63,892,000 | $-3,525,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Financing Cash Flow | $10,450,000 | $-9,000 | $0 | $-67,008,000 |
| Cash Flow From Continuing Financing Activities | $10,450,000 | $-9,000 | $0 | $-67,008,000 |
| Net Other Financing Charges | - | $-14,000 | - | - |
| Cash Dividends Paid | - | - | $0 | $-75,003,000 |
| Common Stock Dividend Paid | - | - | $0 | $-75,003,000 |
| Issuance Of Capital Stock | - | - | - | $0 |
| Net Common Stock Issuance | - | - | - | $0 |
| Common Stock Issuance | - | - | - | $0 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Debt | $10,250,000 | $0 | - | - |
| Interest Paid Supplemental Data | $400,000 | $0 | - | - |
| Income Tax Paid Supplemental Data | $85,000 | $141,000 | - | $0 |
| End Cash Position | $172,677,000 | $200,023,000 | $157,306,000 | $236,983,000 |
| Beginning Cash Position | $200,023,000 | $157,306,000 | $236,983,000 | $237,366,000 |
| Effect Of Exchange Rate Changes | $-5,529,000 | $-46,000 | $-961,000 | $705,000 |
| Changes In Cash | $-21,817,000 | $42,763,000 | $-78,716,000 | $-1,088,000 |
| Proceeds From Stock Option Exercised | $200,000 | $5,000 | $0 | $7,995,000 |
| Net Issuance Payments Of Debt | $10,250,000 | $0 | - | - |
| Net Short Term Debt Issuance | $10,250,000 | $0 | - | - |
| Short Term Debt Issuance | $10,250,000 | $0 | - | - |
| Net Investment Purchase And Sale | $0 | $61,859,000 | $-63,307,000 | $0 |
| Sale Of Investment | $0 | $61,859,000 | - | - |
| Net PPE Purchase And Sale | $-1,304,000 | $-362,000 | $-585,000 | $-3,525,000 |
| Purchase Of PPE | $-1,304,000 | $-362,000 | $-585,000 | $-3,525,000 |
| Change In Working Capital | $-1,459,000 | $2,719,000 | $7,600,000 | $79,748,000 |
| Change In Payables And Accrued Expense | $-1,265,000 | $2,109,000 | $741,000 | $-279,000 |
| Change In Accrued Expense | $-877,000 | $1,895,000 | $229,000 | $23,000 |
| Change In Payable | $-388,000 | $214,000 | $512,000 | $-302,000 |
| Change In Account Payable | $-364,000 | $91,000 | $357,000 | $-514,000 |
| Change In Tax Payable | $-24,000 | $123,000 | $155,000 | $212,000 |
| Change In Income Tax Payable | $-24,000 | $123,000 | $155,000 | $212,000 |
| Change In Prepaid Assets | $-271,000 | $-160,000 | $334,000 | $-352,000 |
| Change In Receivables | $77,000 | $829,000 | $7,340,000 | $1,733,000 |
| Stock Based Compensation | $1,753,000 | $3,262,000 | $5,062,000 | $4,463,000 |
| Depreciation Amortization Depletion | $1,745,000 | $1,744,000 | $2,614,000 | $2,648,000 |
| Depreciation And Amortization | $1,745,000 | $1,744,000 | $2,614,000 | $2,648,000 |
| Depreciation | $1,745,000 | $1,744,000 | $2,614,000 | $2,648,000 |
| Net Foreign Currency Exchange Gain Loss | $5,529,000 | $-1,893,000 | $2,800,000 | $0 |
| Net Income From Continuing Operations | $-38,531,000 | $-24,557,000 | $-32,900,000 | $-17,414,000 |
| Change In Other Working Capital | - | $-59,000 | $-815,000 | $78,646,000 |
| Purchase Of Investment | - | - | $-63,307,000 | $0 |
| Changes In Account Receivables | - | - | $0 | $4,113,000 |
| Net Business Purchase And Sale | - | - | - | $0 |
| Sale Of Business | - | - | - | $0 |
| Gain Loss On Sale Of Business | - | - | - | $0 |